What is PreventionGenetics?
Founded in 2004 and headquartered in Marshfield, Wisconsin, PreventionGenetics operates as a premier CLIA and ISO 15189:2012 accredited clinical laboratory. The company distinguishes itself through a comprehensive portfolio of genetic testing services, specifically tailored for clinically relevant genes. Its flagship offerings, including the PGnome whole genome sequencing and PGxome whole exome sequencing platforms, represent the cutting edge of modern medical diagnostics. By prioritizing rigorous quality control and cost-effective delivery models, the firm serves as a critical partner for healthcare providers engaged in hereditary disease screening, carrier testing, and the burgeoning field of personalized medicine.
How much funding has PreventionGenetics raised?
PreventionGenetics has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in PreventionGenetics
PPP
Public-Private Partnership
What's next for PreventionGenetics?
With this major enterprise-level funding, PreventionGenetics is well-positioned to accelerate its technological roadmap and broaden its international market reach. The strategic allocation of this capital will likely focus on enhancing laboratory throughput and refining the analytical pipelines required for complex genomic interpretation. As the healthcare industry shifts toward data-driven, patient-centric care, the company is poised to leverage its diagnostic expertise to influence clinical outcomes significantly. Future growth initiatives will likely involve the integration of novel bioinformatics tools and the expansion of its testing menu to address emerging genetic markers, further cementing its status as a leader in the molecular diagnostics landscape.
See full PreventionGenetics company page
